Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088512 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7339985 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL645674 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| Water SCHEMBL10565338 | 0.99 | ACE (0.54) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7348554 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7348550 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL10567698 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL6627295 | 0.88 | ACE (0.43) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL14078890 | 0.87 | ACE (0.42) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL10567318 | 0.87 | ACE (0.64) | ACEMMECYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-05-29 | — | — | US | disclosed |
| EP-0955310-A1 | New derivatives of (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino /1,2-a/ /1,2/ diazepine-1-carboxylic acid, process for their preparation and use for preparation of pharmaceutical agents | HOECHST MARION ROUSSEL (FR) | 1999-11-10 | — | — | EP | disclosed |
| EP-0640086-B1 | MERCAPTOACETYLAMIDO PYRIDAZO[ 1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMA INC (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0599444-B1 | Dual action inhibitors | SQUIBB & SONS INC (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5654294-A | CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0783002-A2 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646276-A | ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5366973-A | Enkephalinase inhibitors, bradykinin inhibitors or inhibitors of angiotensin converting enzymes as analgesics, diuretics or hypotensive agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4772701-A | Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4658024-A | Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | HRH4, HRH3, HRH2 | ACE 2615/4885MME 2031/4885CASP1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.